MEA measurements using the Maestro™ MEA System

Measuring the extracellular field potential (EFP) of hiPSC-derived cardiomyocytes can be used to detect drug-induced effects on the electrophysiology of the cells. EFPs can be obtained noninvasively using microelectrode array (MEA) technology without the need for dyes. The multi-well Maestro™ MEA system (Axion BioSystems) enables EFP recordings in various multi-well plates.

User guide

Cor.4U® and Pluricyte® Cardiomyocytes are optimized for use on the Maestro™ MEA System

The use of Cor.4U® and Pluricyte® Cardiomyocytes in combination with the Maestro™ MEA system has been optimized extensively. Combining these technologies enables detailed electrophysiological detection of potential cardioactive and proarrhythmic effects of test compounds in 48- and 96-well plate formats.

Cor.4U® and Pluricyte® Cardiomyocytes in combination with the Maestro™ MEA system provide a highly relevant in vitro assay platform to study the cardiac safety or efficacy profile of compounds during drug development.

You can find our recommendations on how to combine our cardiomyocytes with the Maestro™ MEA system on 48- and 96-well plate formats for electrophysiology measurements in the following User Guides:

User Guides:


Cardiac safety assessment using hiPSC-derived cardiomyocytes in combination with the Maestro™ MEA system

Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology of Cor.4U® and Pluricyte® Cardiomyocytes using the Maestro™ MEA system. Both Pluricyte® Cardiomyocytes and Cor.4U® Cardiomyocytes show the expected pharmacological responses to reference compounds in a reproducible manner. Below, an example is shown of the effect of the reference compound, E4031, in Cor.4U® Cardiomyocytes.

E4031 induced a prolongation in the field potential duration of Cor.4U® Cardiomyocytes

E4031 is a hERG channel blocker that is expected to delay the repolarization phase, resulting in a prolonged field potential duration (FPD) and ultimately proarrhythmic events. The induced concentration-dependent increase of the FPD in Cor.4U® Cardiomyocytes is shown here (first panel) by an overlay of averaged field potential waveforms. At concentrations of 100 nM E4031, TdP-like arrhythmias were observed (second panel).

Download the complete application notes here: